Summary

The patient monitoring devices market is projected to reach USD 76.11 billion by 2031, up from USD 55.60 billion in 2026, at a CAGR of 6.4%.

Continuous technological innovation and increasing adoption of connected healthcare technologies are significantly driving growth in the patient monitoring devices market. Advancements in patient monitoring systems, including wearable devices, continuous glucose monitoring (CGM), remote patient monitoring platforms, and AI-enabled analytics, offer real-time health tracking, improved clinical decision-making, and enhanced patient outcomes. These technologies support continuous monitoring, reduce dependence on hospitals, and enable early detection of health deterioration. Additionally, innovations in device design have led to compact, wireless, and user-friendly systems, making them more suitable for hospital and home-care settings. Manufacturers are increasingly integrating smart features such as cloud connectivity, mobile applications, predictive analytics, and telehealth compatibility. This ongoing innovation cycle is accelerating the replacement of traditional monitoring systems and driving sustained global demand for advanced patient monitoring devices.

Based on product: The patient monitoring devices market includes multiparameter monitors, blood glucose monitoring devices (CGM and SMBG), wearable monitoring devices, EEG, EMG, ICP, ECG, ILR, MCT, pulse oximeters, fetal & neonatal monitors, blood pressure monitoring devices, hemodynamic monitoring systems, spirometers, and capnography devices. Among these, blood glucose monitoring devices, particularly continuous glucose monitoring (CGM) systems, represent a major growth-driving subsegment. The dominance of this segment is driven primarily by the rising global prevalence of diabetes and the growing need for continuous disease management. CGM and wearable glucose monitoring devices provide real-time glucose insights that support timely treatment decisions and improve patient outcomes. Strong adoption across hospitals, clinics, and home care settings, coupled with rising demand for preventive healthcare, home-based monitoring, smartphone connectivity, and connected healthcare platforms, continues to strengthen the market position of blood glucose monitoring devices.

Based on end user: Hospitals and clinics account for the largest share of the patient monitoring devices market due to their central role in managing acute and chronic conditions requiring continuous patient surveillance. These facilities routinely utilize patient monitoring systems across general wards, intensive care units (ICUs), and emergency & trauma centers to track critical parameters such as heart rate, blood pressure, oxygen saturation, and glucose levels. The growing prevalence of cardiovascular diseases, diabetes, and respiratory disorders has significantly increased demand for real-time monitoring and early clinical intervention. Additionally, hospitals and clinics benefit from advanced healthcare infrastructure, skilled professionals, and integration of connected monitoring technologies. Ongoing investments in critical care capabilities and digital healthcare solutions further drive the adoption of patient monitoring devices, reinforcing the dominance of hospitals and clinics in the market.

North America’s well-developed healthcare infrastructure plays a crucial role in supporting the widespread adoption of patient monitoring devices. The region has an extensive network of hospitals, specialty clinics, and advanced care facilities equipped with modern monitoring technologies to efficiently manage acute and chronic conditions. Healthcare systems across the US and Canada are characterized by strong clinical protocols, high healthcare spending, and highly trained professionals, enabling seamless integration of patient monitoring solutions into routine care. Additionally, the growing adoption of continuous glucose monitoring systems, cardiac monitoring devices, wearable technologies, and remote patient monitoring platforms supports early diagnosis and timely intervention. Regular investments in digital health technologies and continuous upgrades of monitoring systems further contribute to sustained demand. The presence of a robust healthcare ecosystem ensures consistent utilization and adoption of patient monitoring devices across multiple care settings.
A breakdown of the primary respondents (supply-side) for the patient monitoring devices market referred to in this report is provided below:
・ By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
・ By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
・ By Region: North America: 34%, Europe: 27%, Asia Pacific: 30%, Latin America: 6%, Middle East & Africa: 2% and GCC Countries: 2%
Prominent players in the patient monitoring devices market include Medtronic Plc (Ireland), Abbott Laboratories (US), Dexcom, Inc. (US), GE HealthCare (US), Philips Healthcare (Netherlands), Nihon Kohden Corporation (Japan), Mindray Medical International Ltd. (China), Edwards Lifesciences Corporation (US), Getinge AB (Sweden), Baxter International Inc. (US), Drägerwerk AG & Co. KGaA (Germany), Boston Scientific Corporation (US), Masimo Corporation (US), Omron Corporation (Japan), ARCHIMED SAS (Natus Medical) (France), Compumedics Limited (Australia), and Nonin Medical, Inc. (US), among others.

Research Coverage
The report evaluates the patient monitoring devices market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants in the patient monitoring devices market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the patient monitoring devices market.
This report provides insights into the following points:
・Analysis of key drivers (rising prevalence of chronic diseases such as diabetes and cardiovascular disorders, growing aging population requiring continuous monitoring and long-term healthcare management, increasing demand for remote patient monitoring and home healthcare solutions, rapid adoption of wearable and connected healthcare technologies, technological advancements in AI-enabled and cloud-integrated monitoring systems), restraints (high cost of advanced monitoring systems, data privacy and cybersecurity concerns, stringent regulatory approval requirements for medical devices), opportunities (expansion of remote patient monitoring platforms, development of low-cost and portable monitoring devices, growing adoption of home-based and preventive healthcare solutions), and challenges (limited healthcare infrastructure in developing regions, interoperability issues across connected monitoring platforms, reimbursement and adoption barriers in emerging markets)
・Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global patient monitoring devices market.
・Market Development: Thorough knowledge and analysis of the profitable rising markets by product, end user, and region.
・Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global patient monitoring devices market
・Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global patient monitoring devices market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 INCLUSIONS AND EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 39
1.4 STAKEHOLDERS 39
1.5 SUMMARY OF CHANGES 40
2 EXECUTIVE SUMMARY 41
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND START DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS SHAPING MARKET 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46
3 PREMIUM INSIGHTS 47
3.1 PATIENT MONITORING DEVICES MARKET OVERVIEW 47
3.2 NORTH AMERICA: PATIENT MONITORING DEVICES MARKET, BY PRODUCT AND COUNTRY (2025) 48
3.3 PATIENT MONITORING DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
3.4 PATIENT MONITORING DEVICES MARKET, BY REGION (2024–2031) 50
3.5 PATIENT MONITORING DEVICES MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Emergence of predictive analytics in vital sign monitors 52
4.2.1.2 Growing preference for wearable patient monitoring devices, biosensors, and smart implants 53
4.2.1.3 Availability of wireless monitoring devices 53
4.2.1.4 Expansion of telehealth services and remote monitoring capabilities 54
4.2.1.5 Growing incidence of chronic diseases 54
 
4.2.2 RESTRAINTS 56
4.2.2.1 Risks associated with invasive monitoring devices 56
4.2.2.2 High cost of patient monitoring products and inadequate reimbursement 56
4.2.3 OPPORTUNITIES 57
4.2.3.1 Integration with electronic health records (EHRs) 57
4.2.3.2 Expansion of remote patient monitoring in home healthcare settings 58
4.2.4 CHALLENGES 58
4.2.4.1 Lack of personnel and limited awareness & education for patient monitoring devices 58
4.2.4.2 Increased pricing pressure on market players 59
4.3 UNMET NEEDS AND WHITE SPACES 60
4.3.1 UNMET NEEDS IN PATIENT MONITORING DEVICES MARKET 60
4.3.2 WHITE SPACE OPPORTUNITIES 61
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 62
4.4.1 INTERCONNECTED MARKETS 62
4.4.2 CROSS-SECTOR OPPORTUNITIES 62
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 63
5 INDUSTRY TRENDS 64
5.1 PORTER’S FIVE FORCES ANALYSIS 64
5.1.1 THREAT OF NEW ENTRANTS 65
5.1.2 THREAT OF SUBSTITUTES 65
5.1.3 BARGAINING POWER OF SUPPLIERS 66
5.1.4 BARGAINING POWER OF BUYERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.2 MACROECONOMIC OUTLOOK 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS AND FORECAST 66
5.2.3 TRENDS IN GLOBAL PATIENT MONITORING DEVICES INDUSTRY 68
5.2.4 TRENDS IN GLOBAL HEALTHCARE & MEDICAL DEVICES INDUSTRY 68
5.3 SUPPLY CHAIN ANALYSIS 69
5.3.1 PROMINENT COMPANIES 69
5.3.2 SMALL & MEDIUM-SIZED COMPANIES 69
5.3.3 END USERS 69
5.4 VALUE CHAIN ANALYSIS 70
5.4.1 RESEARCH & DEVELOPMENT 70
5.4.2 PROCUREMENT AND PRODUCT DEVELOPMENT 70
5.4.3 MARKETING, SALES, DISTRIBUTION, AND POST-SALES SERVICES 70
5.5 ECOSYSTEM ANALYSIS 71
5.6 PRICING ANALYSIS 72
5.6.1 AVERAGE SELLING PRICE, BY PRODUCT (2025) 72
5.6.2 AVERAGE SELLING PRICE, BY REGION (2025) 73
5.7 TRADE ANALYSIS 75
5.7.1 IMPORT SCENARIO (HS CODE 9018) 76
5.7.2 EXPORT DATA (HS CODE 9018) 76
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 77
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.10 INVESTMENT AND FUNDING SCENARIO 79
5.11 CASE STUDY ANALYSIS 79
5.11.1 CASE STUDY 1: SCALING REMOTE CARDIAC MONITORING 79
5.11.2 CASE STUDY 2: IMPROVING CHRONIC DISEASE MANAGEMENT THROUGH RPM 80
5.11.3 CASE STUDY 3: ENHANCING PATIENT SURVEILLANCE IN ACUTE CARE SETTINGS 80
5.12 IMPACT OF US TARIFFS—PATIENT MONITORING DEVICES MARKET 80
5.12.1 INTRODUCTION 80
5.12.2 KEY TARIFF RATES 81
5.12.3 PRICE IMPACT ANALYSIS 82
5.12.4 IMPACT ON COUNTRIES/REGIONS 83
5.12.4.1 North America 83
5.12.4.2 Europe 83
5.12.4.3 Asia Pacific 83
5.12.5 IMPACT ON END-USE INDUSTRIES 83
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 85
6.1 KEY EMERGING TECHNOLOGIES 85
6.1.1 SMART WEARABLE MONITORING DEVICES 85
6.1.2 VITAL SIGN MONITORS 85
6.2 COMPLEMENTARY TECHNOLOGIES 86
6.2.1 REMOTE PATIENT MONITORS 86
6.2.2 AI & IOT 86
6.3 TECHNOLOGY/PRODUCT ROADMAP 87
6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 87
6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 87
6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 88
6.4 PATENT ANALYSIS 89
6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 90
6.5 FUTURE APPLICATIONS 90
6.5.1 AI-ENABLED REMOTE PATIENT MONITORING & PREDICTIVE HEALTH ANALYTICS 91
6.5.2 HOME-BASED CHRONIC DISEASE MANAGEMENT & TELEHEALTH INTEGRATION 91
6.5.3 SMART HOSPITALS & INTEGRATED CLINICAL MONITORING NETWORKS 91
 
6.6 IMPACT OF AI/GEN AI ON PATIENT MONITORING DEVICES MARKET 92
6.6.1 TOP USE CASES AND MARKET POTENTIAL 92
6.6.2 CASE STUDIES OF AI IMPLEMENTATION IN PATIENT MONITORING DEVICES MARKET 93
6.6.3 INTERCONNECTED/ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 93
6.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PATIENT MONITORING DEVICES MARKET 94
7 REGULATORY LANDSCAPE 95
7.1 REGIONAL REGULATIONS AND COMPLIANCE 95
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
7.1.2 INDUSTRY STANDARDS 99
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
8.1 DECISION-MAKING PROCESS 100
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 100
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
8.2.2 KEY BUYING CRITERIA 101
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 102
8.5 MARKET PROFITABILITY 103
8.5.1 REVENUE POTENTIAL 103
8.5.2 COST DYNAMICS 103
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
9 PATIENT MONITORING DEVICES MARKET, BY PRODUCT 105
9.1 INTRODUCTION 106
9.2 BLOOD GLUCOSE MONITORING DEVICES 107
9.2.1 SELF-MONITORING BLOOD GLUCOSE DEVICES 108
9.2.1.1 Rising adoption of integrated glucose monitoring devices to drive growth 108
9.2.2 CONTINUOUS GLUCOSE MONITORING DEVICES 110
9.2.2.1 Product launches and evolving reimbursement scenarios for continuous monitoring devices to drive market growth 110
9.2.3 WEARABLE GLUCOSE MONITORING DEVICES 112
9.2.3.1 Growing patient inclination towards wearable monitors to boost the market 112
9.3 CARDIAC MONITORING DEVICES 113
9.3.1 ECG DEVICES 115
9.3.1.1 Low cost and wide applications of ECG devices to drive market growth 115
9.3.2 IMPLANTABLE LOOP RECORDERS 117
9.3.2.1 High cost and limited applications to limit growth 117
9.3.3 EVENT MONITORS 118
9.3.3.1 Emergence of portable and wireless event monitors to drive market growth 118
9.3.4 MCT MONITORS 119
9.3.4.1 Availability of alternate technologies to hinder market growth 119
9.3.5 SMART/WEARABLE ECG MONITORS 121
9.3.5.1 Need to minimize treatment costs for CVD patients to increase adoption of smart/wearable ECG monitors 121
9.4 MULTIPARAMETER MONITORING DEVICES 123
9.4.1 LOW-ACUITY MONITORS 125
9.4.1.1 Increasing adoption of low-acuity monitors in general wards to drive market growth 125
9.4.2 MID-ACUITY MONITORS 126
9.4.2.1 Rising geriatric population to increase market growth 126
9.4.3 HIGH-ACUITY MONITORS 127
9.4.3.1 Increasing partnerships between manufacturers and hospitals & clinics to drive device sales 127
9.5 RESPIRATORY MONITORING DEVICES 128
9.5.1 PULSE OXIMETERS 130
9.5.1.1 Rising adoption of pulse oximeters in home care settings to drive market growth 130
9.5.2 SPIROMETERS 131
9.5.2.1 Technological advancements to increase adoption of spirometers 131
9.5.3 CAPNOGRAPHS 133
9.5.3.1 Product development and growing commercial acceptance to drive market growth 133
9.5.4 PEAK FLOW METERS 134
9.5.4.1 Low preference for peak flow meters due to high variability in measurements from different devices, to hinder market growth 134
9.6 TEMPERATURE MONITORING DEVICES 136
9.6.1 HANDHELD TEMPERATURE MONITORING DEVICES 137
9.6.1.1 Advantages associated with handheld temperature monitoring devices to drive market growth 137
9.6.2 TABLE-TOP TEMPERATURE MONITORING DEVICES 139
9.6.2.1 Increasing risks associated with hypothermia during surgeries to drive demand for table-top devices 139
9.6.3 WEARABLE CONTINUOUS MONITORING DEVICES 141
9.6.3.1 Versatile functionalities offered by wearable continuous monitoring devices to drive demand 141
9.6.4 INVASIVE TEMPERATURE MONITORING DEVICES 142
9.6.4.1 Risk of bloodstream infections associated with catheter usage to hinder market for invasive devices 142
9.6.5 SMART TEMPERATURE MONITORING PATCHES 144
9.6.5.1 Long-term monitoring capabilities of smart patches to drive market growth 144
 
9.7 HEMODYNAMIC/PRESSURE MONITORING DEVICES 146
9.7.1 HEMODYNAMIC MONITORS 147
9.7.1.1 Influx of VC funding to drive market growth 147
9.7.2 BLOOD PRESSURE MONITORS 149
9.7.2.1 Development of wearable blood pressure monitors to drive market growth 149
9.7.3 DISPOSABLES 150
9.7.3.1 Growing number of surgical procedures to drive growth in disposables market 150
9.8 FETAL & NEONATAL MONITORING DEVICES 151
9.8.1 FETAL MONITORING DEVICES 153
9.8.1.1 Rising prevalence of obstetric complications to drive market growth 153
9.8.2 NEONATAL MONITORING DEVICES 155
9.8.2.1 Rising number of neonatal care facilities worldwide to drive market 155
9.9 NEUROMONITORING DEVICES 157
9.9.1 EEG MACHINES 158
9.9.1.1 Growing applications and technological advancements to favor market growth 158
9.9.2 EMG MACHINES 160
9.9.2.1 Availability of reimbursements for EMG-assisted surgeries to boost product demand 160
9.9.3 CEREBRAL OXIMETERS 161
9.9.3.1 Growing cases of hypoxia during surgical procedures to drive market growth 161
9.9.4 ICP MONITORS 163
9.9.4.1 Growing incidence of post-surgical cerebrovascular complications and TBIs to support adoption of ICP monitors 163
9.9.5 MEG MACHINES 164
9.9.5.1 High implementation and maintenance costs of MEG devices hinder market growth 164
9.9.6 TCD MACHINES 165
9.9.6.1 Rising prevalence of strokes and cerebrovascular disorders to contribute to market growth 165
9.10 WEIGHT MONITORING DEVICES 167
9.10.1 DIGITAL WEIGHT MONITORING DEVICES 168
9.10.1.1 Consumer preference for digital scales—a key market driver 168
9.10.2 ANALOG WEIGHT MONITORING DEVICES 170
9.10.2.1 Rising prevalence of obesity and low cost of analog scales to support market growth 170
9.11 OTHER PATIENT MONITORING DEVICES 171
 
10 PATIENT MONITORING DEVICES MARKET, BY END USER 174
10.1 INTRODUCTION 175
10.2 HOSPITALS & CLINICS 175
10.2.1 ABILITY TO AFFORD HIGH INSTALLATION & MAINTENANCE COSTS OF PATIENT MONITORING TECHNOLOGIES TO BOOST MARKET 175
10.3 AMBULATORY SURGICAL CENTERS 177
10.3.1 COST-EFFECTIVENESS AND CONVENIENCE TO DRIVE DEMAND FOR AMBULATORY CARE 177
10.4 HOME CARE SETTINGS 178
10.4.1 REDUCED COST AND CONTINUOUS MONITORING OF VITAL INFORMATION IN HOME SETTINGS TO BOOST GROWTH 178
10.5 OTHER END USERS 179
11 PATIENT MONITORING DEVICES MARKET, BY REGION 181
11.1 INTRODUCTION 182
11.2 NORTH AMERICA 183
11.2.1 US 189
11.2.1.1 Growing number of FDA approvals for patient monitoring devices to support market growth 189
11.2.2 CANADA 196
11.2.2.1 Growing public-private funding for research to drive market growth 196
11.3 EUROPE 204
11.3.1 GERMANY 210
11.3.1.1 Rising healthcare expenditure and manufacturer expansion to boost market growth 210
11.3.2 UK 216
11.3.2.1 Increasing public & private investments to contribute to market growth 216
11.3.3 FRANCE 222
11.3.3.1 Statutory health insurance system to support market growth 222
11.3.4 ITALY 228
11.3.4.1 Rising incidence of lifestyle diseases to drive adoption of patient monitoring devices 228
11.3.5 SPAIN 234
11.3.5.1 Growing number of surgical procedures to drive market growth in Spain 234
11.3.6 REST OF EUROPE 240
11.4 ASIA PACIFIC 246
11.4.1 JAPAN 253
11.4.1.1 Large geriatric population and favorable reimbursement scenario to support market growth 253
11.4.2 CHINA 259
11.4.2.1 Growing focus of local and international market players to favor market growth 259
 
11.4.3 INDIA 265
11.4.3.1 Increasing government-implemented healthcare initiatives to support market growth 265
11.4.4 AUSTRALIA 271
11.4.4.1 R&D tax incentive program to support market growth 271
11.4.5 SOUTH KOREA 277
11.4.5.1 Supportive government initiatives to drive market growth 277
11.4.6 REST OF ASIA PACIFIC 283
11.5 LATIN AMERICA 290
11.5.1 BRAZIL 296
11.5.1.1 Brazil to dominate LATAM market 296
11.5.2 MEXICO 302
11.5.2.1 Favorable investment scenario for medical device manufacturers to drive market growth 302
11.5.3 REST OF LATIN AMERICA 308
11.6 MIDDLE EAST & AFRICA 315
11.6.1 AWARENESS INITIATIVES TO DRIVE ADOPTION OF PATIENT MONITORING DEVICES 315
11.7 GCC COUNTRIES 321
11.7.1 HEALTHCARE DIGITALIZATION INITIATIVES TO ACCELERATE PATIENT MONITORING DEVICE ADOPTION IN GCC 321
12 COMPETITIVE LANDSCAPE 328
12.1 OVERVIEW 328
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 328
12.3 REVENUE ANALYSIS 329
12.4 MARKET SHARE ANALYSIS 330
12.4.1 GLOBAL BLOOD GLUCOSE MONITORING DEVICES MARKET SHARE,
BY KEY PLAYER, 2025 330
12.4.2 GLOBAL CARDIAC MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2025 331
12.4.3 GLOBAL MULTIPARAMETER MONITORING DEVICES MARKET SHARE,
BY KEY PLAYER, 2025 332
12.4.4 GLOBAL HEMODYNAMIC/PRESSURE MONITORING DEVICES MARKET SHARE, BY KEY PLAYER, 2025 332
12.4.5 GLOBAL FETAL & NEONATAL MONITORING DEVICES MARKET SHARE,
BY KEY PLAYER, 2025 333
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 335
12.5.1 STARS 335
12.5.2 EMERGING LEADERS 335
12.5.3 PERVASIVE PLAYERS 335
12.5.4 PARTICIPANTS 335
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 337
12.5.5.1 Company footprint 337
12.5.5.2 Region footprint 338
12.5.5.3 Product footprint 339
12.5.5.4 End-user footprint 340
12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2025 341
12.6.1 PROGRESSIVE COMPANIES 341
12.6.2 RESPONSIVE COMPANIES 341
12.6.3 DYNAMIC COMPANIES 341
12.6.4 STARTING BLOCKS 341
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 343
12.6.5.1 Detailed list of key startups/SMEs 343
12.6.5.2 Competitive benchmarking of key startups/SMEs, 2025 344
12.7 COMPANY VALUATION & FINANCIAL METRICS 345
12.8 BRAND/PRODUCT COMPARISON 346
12.9 COMPETITIVE SCENARIO 347
12.9.1 PRODUCT LAUNCHES & APPROVALS 347
12.9.2 DEALS 347
12.9.3 EXPANSIONS 348
13 COMPANY PROFILES 349
13.1 KEY PLAYERS 349
13.1.1 MEDTRONIC 349
13.1.1.1 Business overview 349
13.1.1.2 Products offered 350
13.1.1.3 Recent developments 353
13.1.1.3.1 Product launches & approvals 353
13.1.1.3.2 Deals 354
13.1.1.4 MnM view 355
13.1.1.4.1 Right to win 355
13.1.1.4.2 Strategic choices 355
13.1.1.4.3 Weaknesses and competitive threats 355
13.1.2 ABBOTT LABORATORIES 356
13.1.2.1 Business overview 356
13.1.2.2 Products offered 357
13.1.2.3 Recent developments 358
13.1.2.3.1 Product launches & approvals 358
13.1.2.3.2 Deals 360
13.1.2.4 MnM view 360
13.1.2.4.1 Right to win 360
13.1.2.4.2 Strategic choices 360
13.1.2.4.3 Weaknesses & competitive threats 361
 
13.1.3 DEXCOM, INC. 362
13.1.3.1 Business overview 362
13.1.3.2 Products offered 363
13.1.3.3 Recent developments 364
13.1.3.3.1 Product launches & approvals 364
13.1.3.3.2 Deals 364
13.1.3.4 MnM view 365
13.1.3.4.1 Right to win 365
13.1.3.4.2 Strategic choices 365
13.1.3.4.3 Weaknesses & competitive threats 365
13.1.4 GE HEALTHCARE 366
13.1.4.1 Business overview 366
13.1.4.2 Products offered 367
13.1.4.3 Recent developments 369
13.1.4.3.1 Product launches & approvals 369
13.1.4.3.2 Deals 369
13.1.4.4 MnM view 370
13.1.4.4.1 Right to win 370
13.1.4.4.2 Strategic choices 370
13.1.4.4.3 Weaknesses & competitive threats 370
13.1.5 PHILIPS HEALTHCARE 371
13.1.5.1 Business overview 371
13.1.5.2 Products offered 372
13.1.5.3 Recent developments 375
13.1.5.3.1 Product launches & approvals 375
13.1.5.3.2 Deals 375
13.1.5.4 MnM view 377
13.1.5.4.1 Right to win 377
13.1.5.4.2 Strategic choices 377
13.1.5.4.3 Weaknesses & competitive threats 377
13.1.6 NIHON KOHDEN CORPORATION 378
13.1.6.1 Business overview 378
13.1.6.2 Products offered 379
13.1.6.3 Recent developments 381
13.1.6.3.1 Product launches & approvals 381
13.1.6.3.2 Deals 381
13.1.7 MINDRAY MEDICAL INTERNATIONAL LTD. 383
13.1.7.1 Business overview 383
13.1.7.2 Products offered 384
13.1.7.3 Recent developments 385
13.1.7.3.1 Product launches & approvals 385
13.1.7.3.2 Deals 386
13.1.8 BD 387
13.1.8.1 Business overview 387
13.1.8.2 Products offered 388
13.1.9 GETINGE AB 390
13.1.9.1 Business overview 390
13.1.9.2 Products offered 391
13.1.9.3 Recent developments 392
13.1.9.3.1 Product launches, enhancements, and approvals 392
13.1.9.3.2 Deals 393
13.1.10 BAXTER INTERNATIONAL (HILL-ROM HOLDINGS, INC.) 394
13.1.10.1 Business overview 394
13.1.10.2 Products offered 395
13.1.11 DRÄGERWERK AG & CO. KGAA 398
13.1.11.1 Business overview 398
13.1.11.2 Products offered 399
13.1.12 BOSTON SCIENTIFIC CORPORATION 402
13.1.12.1 Business overview 402
13.1.12.2 Products offered 403
13.1.12.3 Recent developments 404
13.1.12.3.1 Deals 404
13.1.13 MASIMO CORPORATION 405
13.1.13.1 Business overview 405
13.1.13.2 Products offered 406
13.1.14 OMRON CORPORATION 410
13.1.14.1 Business overview 410
13.1.14.2 Products offered 411
13.1.15 ARCHIMED SAS (NATUS MEDICAL) 415
13.1.15.1 Business overview 415
13.1.15.2 Products offered 415
13.1.15.3 Recent developments 416
13.1.15.3.1 Deals 416
13.1.16 COMPUMEDICS LIMITED 417
13.1.16.1 Business overview 417
13.1.16.2 Products offered 418
13.1.16.3 Recent developments 419
13.1.16.3.1 Deals 419
13.1.17 NONIN MEDICAL, INC. 420
13.1.17.1 Business overview 420
13.1.17.2 Products offered 420
13.1.17.3 Recent developments 421
13.1.17.3.1 Product launches & approvals 421
 
13.2 OTHER PLAYERS 422
13.2.1 BIOTRONIK 422
13.2.2 SCHILLER AG 422
13.2.3 SENSEONICS 424
13.2.4 CARDIOMO 424
13.2.5 VITLS 425
13.2.6 NETEERA 425
13.2.7 QARDIO 426
13.2.8 VIVIFY HEALTH 426
13.2.9 IRHYTHM TECHNOLOGIES, INC. 427
13.2.10 OSYPKA MEDICAL 427
13.2.11 CARDINAL HEALTH 428
13.2.12 MERIT MEDICAL SYSTEMS 429
14 RESEARCH METHODOLOGY 430
14.1 RESEARCH DATA 430
14.1.1 SECONDARY DATA 431
14.1.1.1 Key data from secondary sources 432
14.1.2 PRIMARY DATA 433
14.1.2.1 Key data from primary sources 434
14.1.2.2 Key industry insights 434
14.2 MARKET SIZE ESTIMATION 436
14.3 MARKET BREAKDOWN AND DATA TRIANGULATION 441
14.4 MARKET SHARE ESTIMATION 442
14.5 STUDY ASSUMPTIONS 442
14.6 METHODOLOGY-RELATED LIMITATIONS 442
14.7 RESEARCH LIMITATIONS 442
14.8 RISK ASSESSMENT 443
15 APPENDIX 444
15.1 DISCUSSION GUIDE 444
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 449
15.3 CUSTOMIZATION OPTIONS 451
15.4 RELATED REPORTS 451
15.5 AUTHOR DETAILS 452